BLRX
BioLineRx Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.68
−0.37%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
Market Cap
$13.00M
MomentumView details →
1D Return
−0.37%
YTD Return
−2.89%
RSI (14)
45.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
Market Cap
$13.00M
RSI (14)
45.9
MomentumView details →
1D Return
−0.37%
YTD Return
−2.89%
SummaryUpdated Jun 1, 2026
BioLineRx Ltd. (NASDAQ:BLRX) is a clinical-stage biopharmaceutical company founded in 2003 and headquartered in Hevel Modi'in, Israel. The company has undergone a significant strategic transformation from a development-focused biotech to a hybrid commercial and development organization. Following FDA approval of its lead drug APHEXDA in September 2023, BioLineRx successfully launched its first commercial product while simultaneously executing a major licensing deal with Ayrmid Pharma in 2024 that fundamentally reshaped its business model and financial profile.
Similar companies
Latest newsMore news →
BioLineRx reported its unaudited financial results for the quarter ended June 30, 2026, and provided a corporate update.4d agoBioLineRx Ltd. announced a registered direct offering and concurrent private placement of 1,348,921 American Depositary Shares at $2.78 per ADS, raising approximately $3.75 million.7d ago